Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
Holger Rosenbrock, Michael Desch, Glen Wunderlich
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1557-1566
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 57
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
Targeting SLC transporters: small molecules as modulators and therapeutic opportunities
Avner Schlessinger, Nicole Zatorski, Keino Hutchinson, et al.
Trends in Biochemical Sciences (2023) Vol. 48, Iss. 9, pp. 801-814
Open Access | Times Cited: 32
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 14
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia
Daniela L. Uliana, João Roberto Lisboa, Felipe V. Gomes, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116298-116298
Closed Access | Times Cited: 13
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
In-silico screening based on molecular simulations of 3,4-disubstituted pyrrolidine sulfonamides as selective and competitive GlyT1 inhibitors
Mohamed El fadili, Mohammed Er-rajy, Wafa Ali Eltayb, et al.
Arabian Journal of Chemistry (2023) Vol. 16, Iss. 10, pp. 105105-105105
Open Access | Times Cited: 17
Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia
Katrin H. Preller, Joachim Scholpp, Andreas Wunder, et al.
Biological Psychiatry (2024)
Open Access | Times Cited: 7
Antipsychotic Drugs and Cognitive Function
Lena Feber, Natalie Peter, Virginia Chiocchia, et al.
JAMA Psychiatry (2024)
Closed Access | Times Cited: 7
Monophasic coamorphous sulpiride: a leap in physicochemical attributes and dual inhibition of GlyT1 and P-glycoprotein, supported by experimental and computational insights
Ekta Pardhi, Devendra Singh Tomar, Rahul Khemchandani, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-30
Closed Access | Times Cited: 4
Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Psychiatry Research (2024) Vol. 340, pp. 116126-116126
Open Access | Times Cited: 4
Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia
Ruri Okubo, Motohiro Okada, Eishi Motomura
Biomolecules (2024) Vol. 14, Iss. 9, pp. 1128-1128
Open Access | Times Cited: 4
Therapeutic Potential of DAAO Inhibitors for Cognitive Impairment Associated with Schizophrenia: Learnings from Luvadaxistat
Ryan T. Terry-Lorenzo, Ruicheng Fan, Ni A. Khin, et al.
The International Journal of Neuropsychopharmacology (2025)
Open Access
Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
Abigail Gee, Paola Dazzan, Anthony A. Grace, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access
Schizophrenia Management: Systematic Review of Current Medications and Phase-3 Agents (2008–2024)
Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, et al.
Neuroscience Applied (2025) Vol. 4, pp. 105507-105507
Open Access
Cognitive impairment in schizophrenia: when, what, and is it remediable?
Ashlee Guzman, Philip D. Harvey
Current Opinion in Psychiatry (2025)
Closed Access
Effect of SSR504734, a Selective Glycine Transporter Type 1 Inhibitor, on Seizure Thresholds, Neurotransmitter Levels, and Inflammatory Markers in Mice
Nikola Gapińska, Piotr Właź, Elżbieta Wyska, et al.
ACS Chemical Neuroscience (2025)
Open Access
Modulation of the human GlyT1 by clinical drugs and cholesterol
Na Li, Yiqing Wei, Renjie Li, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Brain Network Resilience and Cognitive Function in Patients with First Episode Schizophrenia Spectrum Disorders
Soyolsaikhan Odkhuu, XiaoChen Tang, Woo-Sung Kim, et al.
Biological Psychiatry (2025)
Closed Access
Glycine Transporter 1 Inhibitors: Predictions on Their Possible Mechanisms in the Development of Opioid Analgesic Tolerance
Anna Rita Galambos, Zsolt Tamás Papp, Imre Boldizsár, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 421-421
Open Access | Times Cited: 3
Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations
Antonio Vita, Sergio Barlati, Roberto Cavallaro, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
GABAergic and inflammatory changes in the frontal cortex following neonatal PCP plus isolation rearing, as a dual-hit neurodevelopmental model for schizophrenia
Jennifer Cale, Ethan J. Chauhan, Joshua J. Cleaver, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 9, pp. 6968-6983
Open Access | Times Cited: 2
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities
Na Ye, Qi Wang, Yue Li, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 2
Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways
Ting Zhang, Chang Liu, Ning Zhong, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10668-10668
Open Access | Times Cited: 2
New directions in psychiatric drug development: promising therapeutics in the pipeline
Linda S. Brady, Sarah H. Lisanby, Joshua A. Gordon
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 8, pp. 835-850
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top